Navigation Links
ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
Date:12/10/2009

hase II, randomized, double-blind, sham controlled trial of microplasmin intravitreal injection (125 μg) for the treatment of focal vitreomacular adhesion (separation of the vitreous from the retina) in patients with exudative (wet) AMD. The trial will enroll approximately 100 patients at up to 20 centers across five European countries. The primary endpoint of the trial is non-surgical resolution of vitreomacular adhesion, defined as the separation of the vitreous from the retina by 28 days. This will be assessed by the Central Reading Center based on optical coherence tomography (OCT) images. Additional measures of efficacy and safety will also be assessed over a one year follow-up period.

Microplasmin has the potential to transform the treatment of a number of other important back of the eye diseases as well as AMD. Microplasmin is currently being evaluated in a Phase III program of approximately 640 patients, for the non-surgical treatment of focal vitreomacular adhesion.

Dr. Patrik De Haes, CEO of ThromboGenics commenting on the announcement said, "We are very pleased to announce the start of a Phase II trial of microplasmin in such a significant condition as AMD. It is increasingly clear that vitreomacular adhesion plays a key role in AMD sufferers with a poorer prognosis. Microplasmin's potential to cleave the vitreous from the retina could therefore represent an important advance in the treatment of this patient group. The start of this trial underlines the potential broad applicability of our lead product, and is another important step as we create a profitable integrated company focused on cutting edge ophthalmic medicines."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III cl
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics and BioInvent Complete Patient Recruitment of Phase II DVT Prophylaxis Study With Anti-Factor VIII (TB-402)
2. ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
3. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
4. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
7. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
8. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
9. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
10. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
11. Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the Morgan Stanley Global Healthcare ... , Presentation date: Tuesday September 9, 2014 , Presentation ... webcast and 30-day archive of this presentation will be available ... Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company ...
(Date:9/2/2014)... N.C. , Sept. 2, 2014  Edison ... announced a partnership with the American Association for ... association of respiratory care specialists. Edison Nation Medical, ... and small business to commercialize their innovation ideas, ... association,s community of more than 50,000 respiratory therapists ...
(Date:9/2/2014)... September 2, 2014 Today, Analysts ... WLP ), Tekmira Pharmaceuticals Corporation (NASDAQ: ... ), Sanofi SA (NYSE: SNY ) and ... notes ahead of publication. To reserve complementary membership, limited ... ,WellPoint Inc. Research Reports ,WellPoint Inc. (WellPoint) posted on ...
Breaking Medicine Technology:Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 2Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 3Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 4Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 5Upcoming Event, Positive Findings, Regulatory Approvals, and Vaccine License - Research Reports on WellPoint, Tekmira, Zoetis, Sanofi and GSK 6
(Date:9/3/2014)... (PRWEB) September 03, 2014 Job seekers ... for their next position can now do both on ... has created a seamless tool for investigating employment and ... (massively open online courses) are closing skills gaps and ... to traditional degree programs and brick and mortar universities. ...
(Date:9/3/2014)... NJ (PRWEB) September 03, 2014 ... will be offering free screenings for depression on ... Townsquare Mall (Macy’s Court). More than 1,000 organizations ... events including hospitals, colleges and military installations. After ... to local resources and agencies that can offer ...
(Date:9/3/2014)... Joulebody, the NYC based juice and vegan ... detox and weight-loss program in time for post-summer ...     Because it’s good for celiac, diabetics, and anyone looking ...     Because using an elimination diet helps build better energy. ... letting go of caffeine, sugar, and excess meat eating ...
(Date:9/2/2014)... Autumn is well under way and famous ... season with worldwide people. Recently, it has made ... ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ), Arvixe, and Bluehost are the ... Since 2002 HostGator has been known as a ... for reliability remains with it today. It is ...
(Date:9/2/2014)... include the sensation of grit in the eye, frequently ... are poorly understood., The researchers base their findings on ... 57) from the TwinsUK cohort, drawn from the registry ... is widely regarded as representative of the UK general ... wide range of diseases and genetic traits over the ...
Breaking Medicine News(10 mins):Health News:iHire Announces Partnership with MOOCtracks 2Health News:Screenings for Depression by Morris Psychological Group, October 9, 2014 from 4:30 to 8:30pm, Rockaway Townsquare Mall (Macy’s Court) 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 2Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 3Health News:Joulebody Launches a Besoke 20-Day Healthy Lifestyle Program 4Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Around 1 in 10 UK women has dry eye disease, requiring artificial tears 2
... 23 WebMD Health Corp. (Nasdaq: WBMD ) ... that executives of WebMD are scheduled to participate at the ... 25, 2009 at 12:40 p.m. ET. Investors, analysts and ... audio broadcast of the presentation over the Internet. The ...
... On Wednesday, February 25, 2009, the Institute for ... roundtable discussion bringing leading scientists in the field of ... significance (MGUS). The event is being cochaired by James ... at the IMBCR and Robert A. Kyle, MD, who ...
... with Crain,s Cleveland Business, today presented a 2009 NorTech ... development of a Biotech Platform to Detect, Monitor, and ... developed a set of diagnostic tests used by physicians ... by determining drug resistance and disease "strength" of the ...
... #1 FOR IMMEDIATE RELEASE , Egg-irony: High cholesterol food ... Chemistry , Researchers in Canada are reporting evidence that ... may reduce another heart disease risk factor high ... that act like a popular group of prescription medications in ...
... TAMPA, Fla., Feb. 23 /PRNewswire/ -- ... data management solutions company, today announced the release ... cleanses, standardizes and integrates data from multiple platforms. ... businesses encompassing small, mid-size and "Fortune 500" companies, ...
... Sunrise Senior Living, Inc. (NYSE: SRZ ) today ... on Monday, March 2, 2009, at 9 a.m. ET to ... Mark Ordan, chief executive officer, and Richard Nadeau, chief financial ... conference call is 877-795-3638 or 719-325-4841 (from outside the U.S.). ...
Cached Medicine News:Health News:International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease 2Health News:Case Western Reserve University faculty named 2009 NorTech Innovation Award winner 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 2Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 3Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 4Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 5Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 6Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 7Health News:American Chemical Society's Weekly PessPac -- Feb. 18, 2009 8Health News:Industry Leading Data Quality and Householding Software Receives New Functionality for Enhanced Performance and Speed 2Health News:Sunrise to Host Conference Call and Webcast to Discuss Fourth-Quarter and Full-Year 2008 Financial Results 2
Human based assayed sera available in three levels for the control of accuracy and precision for up to 25 analytes...
CRP Liquid Conrtols level 2...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Enzymatic Clearance assay for the in vitro quantitative determination of LDL-cholesterol in human serum and plasma....
Medicine Products: